Taken together, these results indicated that the BsAb enhanced the infiltration and cytotoxic ability of CD8-positive T cells in the tumor tissue by targeting MDSCs and M2 TAMs to overcome the inhibitory immune response of the TME. The gene discussed is CD8A; the disease is neoplasm.